CVM Cel Sci Corp

Price (delayed)

$8.83

Market cap

$361.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$366.36M

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients ...

Highlights
The equity has soared by 107% YoY
Cel Sci's quick ratio has increased by 9% YoY and by 3.1% from the previous quarter
The company's EPS fell by 3.4% QoQ but it rose by 3.2% YoY
The gross profit has plunged by 62% YoY and by 58% from the previous quarter
The company's revenue has shrunk by 62% YoY and by 58% QoQ

Key stats

What are the main financial stats of CVM
Market
Shares outstanding
40.91M
Market cap
$361.21M
Enterprise value
$366.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.2
Price to sales (P/S)
1,562.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,618.93
Earnings
Revenue
$226,299
EBIT
-$34.07M
EBITDA
-$31.7M
Free cash flow
-$24.6M
Per share
EPS
-$0.91
Free cash flow per share
-$0.61
Book value per share
$0.72
Revenue per share
$0.01
TBVPS
$1.2
Balance sheet
Total assets
$48.37M
Total liabilities
$19.03M
Debt
$13.26M
Equity
$29.33M
Working capital
$14.04M
Liquidity
Debt to equity
0.45
Current ratio
3.41
Quick ratio
3.32
Net debt/EBITDA
-0.16
Margins
EBITDA margin
-14,009.9%
Gross margin
100%
Net margin
-15,523%
Operating margin
-14,512.3%
Efficiency
Return on assets
-77%
Return on equity
-142.2%
Return on invested capital
-94.9%
Return on capital employed
-80.1%
Return on sales
-15,055.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CVM stock price

How has the Cel Sci stock price performed over time
Intraday
6.26%
1 week
6.39%
1 month
9.69%
1 year
-26.66%
YTD
-24.27%
QTD
1.73%

Financial performance

How have Cel Sci's revenue and profit performed over time
Revenue
$226,299
Gross profit
$226,299
Operating income
-$32.84M
Net income
-$35.13M
Gross margin
100%
Net margin
-15,523%
CVM's net margin has dropped by 192% year-on-year and by 156% since the previous quarter
The operating margin has plunged by 154% from the previous quarter
The gross profit has plunged by 62% YoY and by 58% from the previous quarter
The company's revenue has shrunk by 62% YoY and by 58% QoQ

Growth

What is Cel Sci's growth rate over time

Valuation

What is Cel Sci stock price valuation
P/E
N/A
P/B
12.2
P/S
1,562.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,618.93
The company's EPS fell by 3.4% QoQ but it rose by 3.2% YoY
The equity has soared by 107% YoY
The stock's price to book (P/B) is 45% less than its last 4 quarters average of 22.2
The company's revenue has shrunk by 62% YoY and by 58% QoQ
CVM's P/S is 21% above its last 4 quarters average of 1286.6

Efficiency

How efficient is Cel Sci business performance
The company's return on sales has shrunk by 196% YoY and by 157% QoQ
CVM's return on equity has surged by 67% year-on-year and by 10% since the previous quarter
The return on assets has grown by 24% year-on-year
Cel Sci's return on invested capital has increased by 11% YoY and by 7% QoQ

Dividends

What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CVM.

Financial health

How did Cel Sci financials performed over time
The total assets is 154% more than the total liabilities
The total assets has grown by 32% YoY but it has contracted by 2.5% from the previous quarter
The total liabilities has contracted by 15% YoY and by 8% from the previous quarter
CVM's debt is 55% smaller than its equity
The equity has soared by 107% YoY
The company's debt to equity has shrunk by 55% YoY and by 4.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.